Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 15, 2019
Event: Entry into a Material Definitive Agreement and Unregistered Sales of Equity Securities.
Key Financial Metrics
This filing reports a specific capital raise event rather than periodic financial performance. Key metrics related to the transaction include:
- Shares Issued: 4,444,443 shares of Common Stock.
- Purchase Price: $0.45 per share.
- Aggregate Proceeds: Approximately $2,000,000 (before deducting transaction-related expenses).
- Closing Date: May 15, 2019.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels. A pro forma balance sheet as of March 31, 2019, is referenced as an exhibit but its specific figures are not included in the text.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders resulting from the private placement. The company entered into a Stock Purchase Agreement to sell the shares described above. The transaction was completed on the date of the report.
Guidance, Outlook, and Restrictions
- Lock-Up Period: Purchasers are restricted from selling, pledging, or transferring the shares for six months following the closing (until November 15, 2019).
- Company Restriction: The Company agreed not to sell or announce the sale of Common Stock or equivalents during the same six-month Lock-Up Period without the lead investor's consent.
- Registration Obligation: The Company must use commercially reasonable efforts to file a registration statement for the resale of the shares by August 13, 2019 (90 days post-closing) and maintain its effectiveness until all shares are sold or eligible for Rule 144.
- Investor Status: The sale was conducted as a private placement under Section 4(a)(2) of the Securities Act, with purchasers believed to be accredited investors.
Investor Verification Checklist
- Verify the actual net proceeds after deducting transaction-related expenses, as the $2,000,000 figure is pre-expense.
- Review the Pro Forma Consolidated Condensed Balance Sheet (Exhibit 99.2) to assess the impact on liquidity and capitalization.
- Confirm the identity of the "lead investor" who holds veto power over future equity sales during the lock-up period.
- Monitor the filing of the registration statement for resale of shares by the August 13, 2019 deadline.